Why Fewer Doctors See Reps, and What It Means for Both Sides of the Office Door

Ask a pharmaceutical or medical device rep about the hardest part of the job, and you'll rarely hear "the science" or "the competition." You'll hear "getting in the door."

Ask an office manager the same question from the other side, and you'll hear something like "too many reps, not enough time, and half of them aren't relevant to what we treat."

Both answers are true, and they describe the same problem. Physician access to industry reps has been shrinking for more than a decade, and it hasn't leveled off. Understanding why this is happening, and what it costs each side, is the first step toward fixing it.

The numbers behind the closed door

The decline is well documented. By recent industry estimates, fewer than 35% of physicians now count as rep-accessible, compared with 44% in 2017, and the typical in-person detail now lasts less than two minutes. bluenovius

Specialty care is even tighter. ZS Access Monitor data shows that just 32% of oncology providers are fully accessible, and a ZS study of more than 25,000 physicians found providers average nine in-person rep touchpoints every day. zs

Nine interactions a day, on top of a full patient schedule, charting, prior authorizations and everything else a clinic runs on. It's no surprise that many physicians have cut back on in-person visits and now meet with only a handful of companies. pharmaceuticalcommerce

The trend line is clear. The question is why.

Why access keeps shrinking

1. Physicians have less time than ever

Clinical demands haven't eased. Heavier patient loads and growing administrative work leave physicians with little time for reps, and the data reflects it. When a provider's day is already overbooked, an unscheduled interruption in the hallway is the first thing to go. bluenovius

2. Too many reps chasing the same doctors

Even as field forces shrink through restructuring, the number of reps calling on any given physician remains high. In specialties with active pipelines, the pressure only grows. In oncology, a steady stream of new launches keeps increasing the competition for share of voice among a limited, often overlapping group of customers. Every new product means more reps asking for the same fifteen minutes. zs

3. Consolidation brings policy

As independent practices join hospitals and health systems, rep access decisions often move from the front desk to a corporate policy manual. Many hospitals and health systems already maintain outright bans on sales rep visits, and some states have added their own rules on how drug reps can market to prescribers. p360

Size matters too. An older SK&A survey found that offices with 10 or more physicians were far more likely to refuse rep visits (42%) than offices with just one or two doctors (13.3%), and that practices owned by hospitals or health systems were harder to access because appointments had to be routed through headquarters. The specific figures have shifted since then, but the pattern holds: the bigger and more centralized the organization, the harder the door is to open. Wikipedia

4. Digital habits stuck

The pandemic permanently changed how physicians consume information. Hybrid engagement is now the default, and physicians who got used to virtual interactions during COVID expect digital-first communication as standard. In-person visits now compete with webinars, email and on-demand resources that fit around the clinical day. bluenovius

5. Relevance is often missing

This is the one that gets talked about least, and it may matter most. A cardiology practice doesn't need a visit about a dermatology product. A rural family medicine office has different needs than an academic oncology center. When visits routinely have nothing to do with the patients a practice actually treats, the rational response is to stop taking them. Access restrictions are often less a rejection of reps than a rejection of irrelevance.

What restricted access costs the practice

It's easy to frame declining access as purely a rep problem. It isn't. When a practice shuts the door entirely, it loses things of real value.

Information on new therapies. Reps are often the fastest route to updated clinical data, new indications, and label changes. A practice that doesn't see reps depends on physicians finding that information on their own time.

Patient access support. This is where the loss hurts most. Reps can share approved resources on patient assistance programs, co-pay cards and formulary coverage, and helping with patient access and education is both permissible and valuable. For patients struggling to afford a therapy, a rep who knows the programs can make the difference between starting treatment and walking away from the pharmacy counter. intuitionlabs

Awareness of new ways to get medications. Manufacturers are building new paths to patients. Companies are rolling out home delivery, virtual onboarding and digital support programs, and at least one major company has launched a direct-to-patient fulfillment platform for eligible cash-paying patients. Staff who understand these programs can help patients navigate them. Staff who've never heard of them can't. pharmaceuticalcommerce

Samples and educational materials. For many practices, these still matter, especially for patients starting a new therapy.

The goal for most practices isn't zero rep contact. It's the right rep contact, on the practice's terms.

What restricted access costs reps

For reps, the cost is measured in hours and in credibility.

A rep who can't get a scheduled meeting spends the day on drive time, waiting room time, and "try again next week." Each unproductive stop means less time for the offices where a conversation would actually help patients.

At the same time, the job itself is changing. Reps increasingly rely on analytics and AI to prioritize accounts and personalize hybrid engagement, while the metrics they're judged on are moving away from call volume toward starts, adherence, and time to therapy. In that world, a two-minute doorknob detail isn't just frustrating. It doesn't move the numbers that matter. pharmaceuticalcommerce

What actually improves access

The good news is that access isn't a lost cause. It rewards a different approach, from both sides.

For practices: set the terms instead of closing the door

Practices that manage rep access well tend to share a few habits:

• They decide in advance how many rep meetings they want, when, and in what format, rather than reacting to walk-ins.
• They prioritize by relevance. Reps whose products match the practice's patient population and specialty get priority.
• They make one person responsible. Usually the office manager, with a clear process the whole front desk follows.
• They protect clinical time. Meetings happen at set times, like lunch, so they don't disrupt patient flow.

Structure turns rep access from a daily interruption into a scheduled, useful part of how the practice stays current.

For reps: lead with the practice, not the product

The principle here isn't new. Research going back years has found that rep access improved noticeably when reps truly understood their physicians' practices, and those with more managed care training got better access. pharmexec

That still holds. Reps who earn repeat access tend to:

• Know the practice's specialty mix, patient population, and payer landscape before walking in.
• Bring something useful beyond the detail: access program updates, formulary changes, patient education materials.
• Respect the practice's process and time, even when it means waiting for the right meeting instead of forcing a quick one.
• Treat office staff as partners, not gatekeepers.

Where this is heading

Physician access isn't going to rebound to the levels of the early 2000s, and it probably shouldn't. The old model of high-volume, low-relevance visits wasn't good for physicians, patients, or reps.

What's replacing it is a more structured model: fewer meetings, better matched, scheduled on the practice's terms. Practices get the information and patient support they actually need. Reps spend their time in offices where their products are relevant. Patients benefit from providers who stay current on therapies that apply to them.

That's the model Med Sales Hub was built around. Practices create the meetings they want to host, and reps whose territories and specialties fit those practices can request them, so both sides spend their time on conversations that matter. If your practice is tired of managing rep traffic, or you're a rep tired of lobby time, we'd like to show you how it works.

‍